I-Radicava yisidakamizwa sokuqala se-FDA esamukelekile se-ALS eminyakeni engaphezu kwengu-20
Imithi entsha ebizwa ngokuthi i-Radicava (edaravone) yamukelwa ngo-May 2017 yokwelashwa kwe- amyotrophic lateral sclerosis (ALS) . Yamukelwe eJapane ngaphambi kokuba ivunyiwe e-United States. Lokhu kuyintuthuko ephawulekayo ngoba yisidakamizwa sokuqala se-FDA esamukelekile se-ALS eminyakeni engaphezu kwengu-20.
I-ALS yisifo sezinzwa esenza ubuthakathaka bomzimba futhi bukhuni ngokushesha, okwenza kube nokukhubazeka okuphelele phakathi neminyaka embalwa nje.
Izimpawu zakudala zihlanganisa ubuthakathaka obuthakathaka nokucabangela okucashile okungabandakanya izingalo, imilenze, ubuso noma ulimi.
I-Radicava ingenye yezokwelapha ezimbalwa ezitholakalayo ze-ALS, esinye sezizathu ukuthi le mithi ibaluleke kakhulu. Njengoba i-ALS ivimbela, ukunciphisa noma ukuvimba lesi sifo kungase kunciphise ukukhubazeka futhi kwandise ukuphila kwalabo abahlala nayo.
I-Radicava isebenza kanjani?
I-Radicava ikholelwa ukuthi ivikela ekubhebhekeni kwe-ALS ngokusebenza njenge-antioxidant. Ama-antioxidants avimbela uhlobo lomonakalo emzimbeni owaziwa ngokuthi umonakalo oxidative. Abantu abano-ALS bathole ukuthi banomonakalo wokulimala okwedlulele kunelabo abangenawo ama-ALS, okungenani okungenani abanomthwalo wesifo.
EJapane, icala elingamasonto ayisithupha likaRadicava lisho ukuthi abathintekayo be-ALS abathatha izidakamizwa abaye baqhubeka bebhebhetheka kakhudlwana emsebenzini wabo wansuku zonke kunabalingani be-ALS abangazange bathathe uRadicava.
Usebenzisa kanjani iRadicava?
I-Radicava ithathwe nge-infusion engenayo i-intravenous (IV) futhi kufanele inikezwe ochwepheshe bezempilo. I-infusion ihlala cishe cishe ihora futhi ithathwa nsuku zonke izinsuku ezingu-14 ngokulandelana, ilandelwa ukuphumula kwezinsuku ezingu-14. Ngemuva komjikelezo wokuqala wezinsuku ezingu-28, imijikelezo yokumisa iphindwa ngokuthatha i-Radicava izinsuku ezingu-10 ezinsukwini ezingu-14 zokuqala zomjikelezo, iphindelwe futhi ngekhefu lama-14.
Imiphumela emibi engenzeka
Imiphumela emibi kakhulu ye-Radicava ihlanganisa ukulimaza nokuhlupheka ukuhamba. Ngenkathi ingabonakali njengomphumela ohlangene ovamile, i-Radicava ingase ibangele ukusabela okubangelwa ukwelashwa okunjengezinyosi nokuphefumula ukuphefumula. Ukubhekana nemiphumela emibi lapho kuthatha isidakamizwa okumele kube usizo kuyakukhathazeka ngokuzwakalayo.
Ngaphambi kokukhetha lokwelashwa, qiniseka ukuthi uxoxisana nobungozi bale miphumela emibi nodokotela wakho ukuze uqonde ukuthi zingathinta kanjani isimo sakho esithile nokuthi ungabhekana kanjani nokubhekana nazo.
Ezinye izinketho zokwelapha
Uma unquma ukuthi i-Radicava ikuphi, kubalulekile ukucabangela ezinye izindlela zokwelashwa ezitholakalayo. Ngeshwa, kunemithi embalwa kakhulu etholakalayo kubantu abaphila ne-ALS.
Imithi ebizwa ngokuthi i-Riluzol yavunywa ngo-1996. Le mithi ikholelwa ukuthi isebenza ngokunciphisa isenzo sekhemikhali okuthiwa i-glutamic acid, eyaziwa ngaphezu kokugqugquzela isimiso sezinzwa, okungabangela ukulimala okungapheli emithanjeni.
Ezinye izindlela zokwelapha ze-ALS ziqondiswa ekuqondeni izimpawu njengoba zivela, futhi aziphumeleli ekunciphiseni noma ukuvimba lesi sifo. Isibonelo, imithi yobuhlungu kanye nemithi eyanciphisa ukungakhululeki okubangelwa ukuqina komfutho kungasetshenziswa uma uzwa ubuhlungu noma ubunzima be-muscle.
Ngokufanayo, amadivaysi ezokwelapha njengama-muscular braces, izihlalo zabakhubazekile kanye namatayipi okudla angasiza ukwenza impilo yakho ibe lula nge-ALS, kodwa ayikwazi ukuguqula noma yokuvimba lesi sifo ngokwaso.
Ukuphila nge-ALS ehamba phambili kusho ukuthi abantu bahlushwa ubuthakathaka obuphelele bezingalo, imilenze, umzimba kanye nobuso, ngenkathi bekwazi ukucabanga, ukuzwa, ukubona, ukuzwa nokuhambisa amehlo abo. Ezigabeni eziphambili, abaningi abakwazi ukukhuluma, ukuhlafuna, noma ukugwinya ukudla ngenxa yobuthakathaka bemisipha elawula ukunyakaza komlomo nomlomo. Kodwa-ke, ukuxhumana kungenzeka uma unayo i-ALS, ngoba ungaqonda abanye futhi ungasebenzisa namasu, njengokubuchwepheshe bekhompyutha, ukuxhumana.
Ngokuvamile, i-ALS iholela ekukhubazekeni okukhulu ngisho nokufa phakathi neminyaka embalwa kokuqala kwezimpawu. Ukwelashwa okunciphisa lokhu kuqhubeka kuyathembisa. Ukuxoxa ngezinzuzo zalo ngesimo sakho nodokotela wakho kungcono kakhulu.
Izwi elivela
Ngokusho kwamaCentral for Disease Control and Prevention (CDC), abangaba ngu-12 000-15 000 000 baseMelika njengamanje bahlala ne-ALS, okwenza kube yinto engavamile, kodwa kubaluleke kakhulu kunabo bonke abantu abahluphekile nge-ALS, kanye othandekayo nabangane.
I-ALS ingenye yezinkinga ezingathí sina negazi eziyingozi kakhulu. Esinye sezici ezinzima kunazo zonke zokuphila ne-ALS yukuthi ukusebenza kwengqondo kugcinwa kakhulu kubantu abaningi abane-ALS uma kuqhathaniswa nokwehla ngokomzimba. Ukwazi ukuthi kunezinketho ezimbalwa zokwelapha ezitholakalayo nakho kuphazamisa.
Ukuvunyelwa kukaRadicava ukwelashwa kwe-ALS kuyathembisa. Ukukhula okusheshayo ekuqapheleni lesi sifo, iningi layo ngokusebenzisa inselelo ye-bhakede leqhwa, kungabangela intuthuko yesayensi eyengeziwe esikhathini esizayo. Okwamanje, labo abane-ALS bangase bazuze ngokujoyina iqembu lokusekela noma ngisho nokufunda ukuthi bangathanda yini ukuhlanganyela ekwelapheni kokuhlola njengoba ucwaningo luqhubeka kule ndawo.
> Imithombo:
> Nagase M, et al. Ukucindezeleka okwenziwe nge-oxyidative kweziguli ezine-amyotrophic lateral sclerosis kanye nomphumela wokuphathwa kwe-edaravone. I-Redox Rep. 2016 Meyi; 21 (3): 104-12.
> UMnyango wezeMpilo waseMelika kanye nezinsizakalo zabasebenzi. I-FDA ivumela izidakamizwa ukuphatha i-ALS. 2017.